Dreyer N, Petruski-Ivleva N, Albert L, et al. - This study sought to correlate the risk for COVID-19 symptom persistence by self-reported use of medications for autoimmune disease among participants of an online COVID-19 registry. Researchers performed a community-based online survey collecting weekly data on COVID-19 symptom presentation. They enrolled participants who completed informed consent online, reported a positive COVID-19 test result within 14 days prior to enrollment, and also reported demographics, underlying illnesses, and medication use. The odds of more severe acute illness and symptom persistence approximately 30 days after enrollment were assessed by using Logistic regression. The study enrolled a total of 1,518 COVID-19-positive participants. As per the findings, individuals with underlying autoimmune conditions seem to be especially vulnerable to post-acute sequelae from COVID-19; early intervention might be considered.